Cargando…

Postprandial effects of calcium phosphate supplementation on plasma concentration-double-blind, placebo-controlled cross-over human study

BACKGROUND: The aim of the present study was to examine the postprandial calcium and phosphate concentrations after supplementation with pentacalcium hydroxy-triphosphate (CaP). METHODS: Ten men participated in this double-blind, placebo-controlled, cross-over study. The participants were divided in...

Descripción completa

Detalles Bibliográficos
Autores principales: Trautvetter, Ulrike, Kiehntopf, Michael, Jahreis, Gerhard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3599792/
https://www.ncbi.nlm.nih.gov/pubmed/23510513
http://dx.doi.org/10.1186/1475-2891-12-30
Descripción
Sumario:BACKGROUND: The aim of the present study was to examine the postprandial calcium and phosphate concentrations after supplementation with pentacalcium hydroxy-triphosphate (CaP). METHODS: Ten men participated in this double-blind, placebo-controlled, cross-over study. The participants were divided into two groups. One group consumed bread enriched with CaP (plus 1 g calcium/d) and the other group a placebo product for three weeks. After a two week wash-out, the intervention was switched between the groups for another three weeks. Blood samples were drawn at the beginning (single administration) and at the end (repeated administration) of the intervention periods at 0, 30, 60, 120, 180 and 240 min. Between 0 and 30 min, a test meal, with or without CaP was consumed. The plasma concentrations of calcium and phosphate were examined. One participant dropped out due to personal reasons. RESULTS: CaP supplementation resulted in a significantly higher plasma calcium concentration after 240 min compared to placebo. After repeated CaP administration, the AUC for the increment in plasma calcium concentration was significantly higher compared to placebo. After single and repeated CaP supplementation, plasma phosphate concentration significantly decreased after 30, 60, 120 and 180 min compared to 0 min. The placebo administration resulted in significant decreases after 30, 60 and 120 min compared to 0 min. CONCLUSION: Our results show that CaP contributes to an adequate calcium supply, but without increasing the plasma concentration of phosphate. TRIAL REGISTRATION: http://www.clinicaltrials.gov; NCT01296997